Fast Track Designation Granted for Asimadoline for Diarrhea-Predominant IBS
Tioga Pharmaceuticals announced that asimadoline has been granted fast track designation by the FDA for the treatment of patients with diarrhea-predominant irritable bowel syndrome (D-IBS). Tioga is conducting a multicenter Phase 3 clinical trial evaluating asimadoline in D-IBS, conducted under a Special Protocol Assessment agreement with the FDA for U.S. registration.
Asimadoline is an orally administered small molecule that is a highly selective, peripherally restricted, kappa opioid receptor agonist.
For more information call (858) 677-6077 or visit www.tiogapharma.com.